Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics
Open Access
- 27 November 2020
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (12), 425
- https://doi.org/10.3390/ph13120425
Abstract
The SARS-CoV-2 infection is associated with pulmonary coagulopathy, which determines the deposition of fibrin in the air spaces and lung parenchyma. The resulting lung lesions compromise patient pulmonary function and increase mortality, or end in permanent lung damage for those who have recovered from the COVID-19 disease. Therefore, local pulmonary fibrinolysis can be efficacious in degrading pre-existing fibrin clots and reducing the conversion of lung lesions into lasting scars. Plasminogen is considered a key player in fibrinolysis processes, and in view of a bench-to-bedside translation, we focused on the aerosolization of an orphan medicinal product (OMP) for ligneous conjunctivitis: human plasminogen (PLG-OMP) eye drops. As such, the sterile and preservative-free solution guarantees the pharmaceutical quality of GMP production and meets the Ph. Eur. requirements of liquid preparations for nebulization. PLG-OMP aerosolization was evaluated both from technological and stability viewpoints, after being submitted to either jet or ultrasonic nebulization. Jet nebulization resulted in a more efficient delivery of an aerosol suitable for pulmonary deposition. The biochemical investigation highlighted substantial protein integrity maintenance with the percentage of native plasminogen band > 90%, in accordance with the quality specifications of PLG-OMP. In a coherent way, the specific activity of plasminogen is maintained within the range 4.8–5.6 IU/mg (PLG-OMP pre-nebulization: 5.0 IU/mg). This is the first study that focuses on the technological and biochemical aspects of aerosolized plasminogen, which could affect both treatment efficacy and clinical dosage delivery. Increasing evidence for the need of local fibrinolytic therapy could merge with the availability of PLG-OMP as an easy handling solution, readily aerosolizable for a fast translation into an extended clinical efficacy assessment in COVID-19 patients.This publication has 34 references indexed in Scilit:
- Plasminogen is a critical regulator of cutaneous wound healingThrombosis and Haemostasis, 2016
- Protein stability in pulmonary drug delivery via nebulizationAdvanced Drug Delivery Reviews, 2015
- Effect of formulation on the stability and aerosol performance of a nebulized antibodymAbs, 2014
- Mechanisms of Pharmaceutical Aerosol Deposition in the Respiratory TractAAPS PharmSciTech, 2014
- Particle Transport and Deposition: Basic Physics of Particle KineticsPublished by Wiley ,2013
- Impact of plasminogen on an in vitro wound healing model based on a perfusion cell culture systemMolecular and Cellular Biochemistry, 2008
- Isotonic and Hypertonic Saline Droplet Deposition in a Human Upper Airway ModelJournal of Aerosol Medicine, 2006
- Purification and Characterization of A61Online Journal of Public Health Informatics, 2001
- Targeting Aerosol Deposition in Patients With Cystic FibrosisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2000
- Differential autolysis of human plasmin at various pH levelsThrombosis Research, 1988